• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Fortrea Holdings Inc.

    3/10/25 5:15:35 PM ET
    $FTRE
    Medical Specialities
    Health Care
    Get the next $FTRE alert in real time by email
    8-K
    false 0001965040 0001965040 2025-03-05 2025-03-05

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    March 5, 2025

    Date of Report (Date of earliest event reported)

     

     

    Fortrea Holdings Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-41704   92-2796441
    (State or other jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (I.R.S. Employer
    Identification No.)

     

    8 Moore Drive
    Durham,   North Carolina   27709
    (Address of principal executive offices)   (Zip Code)

    (Registrant’s telephone number including area code) 877-495-0816

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Exchange Act.

     

    Title of Each Class

     

    Trading
    Symbol

     

    Name of exchange on
    which registered

    Common Stock, $0.001 par value   FTRE   The NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On March 5, 2025, the Board of Directors (the “Board”) of Fortrea Holdings Inc. (the “Company”) appointed Erin L. Russell as a Class II director on the Board of the Company, effective March 7, 2025. The appointment is pursuant to the Agreement dated February 21, 2025, by and among the Company and Starboard Value LP and certain of its affiliated entities and natural persons, and as previously reported on the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2025. Ms. Russell shall hold such position as a Class II director until the 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified or until her earlier death, resignation or removal. At the time of this disclosure, Ms. Russell was not named to any committees of the Board, and no decision has been made regarding which committees Ms. Russell will serve.

    Ms. Russell brings extensive experience in finance and healthcare to the position, having served in executive and board roles. She was recently appointed to serve on the board of Modivcare, a technology-enabled healthcare services company, since February 2025, and also serves on the boards of eHealth, Inc., a leading online health insurance marketplace, since July 2021, and Kadant Inc., a global supplier of high-value engineered systems used in process industries worldwide, since January 2019. Her previous board experience in the healthcare sector includes Tivity Health Inc., a leading provider of healthy living, fitness and social engagement solutions, DeVilbiss Healthcare LLC, a company that designs, manufactures and markets respiratory medical products, DynaVox Inc., a communications device manufacturer, and 21st Century Oncology Inc., a provider of state-of-the-art radiation therapy and integrated cancer treatments. Previously, Ms. Russell served as an industry advisor of Starboard Value Acquisition Corporation, a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, from August 2020 until August 2021. Ms. Russell spent 16 years as a principal of Vestar Capital Partners, L.P., a leading private equity firm specializing in management buyouts, recapitalizations, and growth equity investments. Ms. Russell is currently chair of the board of St. Thomas Aquinas Catholic School, where she has served since June 2018, and chair of the advisory board of McIntire School of Commerce and member of advisory board of the Jefferson Scholars Foundation at the University of Virginia, where she has served since June 2016 and April 2008, respectively. Ms. Russell earned her Bachelor of Science in commerce, with a concentration in accounting, from the McIntire School of Commerce at the University of Virginia and her Master of Business Administration from Harvard Business School.

    Ms. Russell will receive compensation for her service as a director in accordance with the Company’s non-employee director compensation policy, a copy of which was filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. Other than as described in this Current Report on Form 8-K, there are no arrangements or understandings between Ms. Russell and any other person pursuant to which she was elected as a director of the Company, and she is not a party to, nor does she have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. She does not have any family relations with any directors or executive officers of the Company.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Fortrea Holdings Inc.
    By:  

    /s/ Stillman Hanson

      Name: Stillman Hanson
      Title: General Counsel and Secretary

    Date: March 10, 2025

    Get the next $FTRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FTRE

    DatePrice TargetRatingAnalyst
    1/8/2026$22.00Hold → Buy
    Truist
    1/6/2026$25.00In-line → Outperform
    Evercore ISI
    12/15/2025$15.00Underweight → Equal Weight
    Barclays
    12/11/2025$21.00Neutral → Buy
    Citigroup
    8/4/2025$9.00Neutral → Outperform
    Robert W. Baird
    5/2/2025$7.00Hold
    Truist
    4/10/2025$6.00Equal Weight → Underweight
    Barclays
    12/11/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    More analyst ratings

    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fortrea upgraded by Truist with a new price target

    Truist upgraded Fortrea from Hold to Buy and set a new price target of $22.00

    1/8/26 8:10:34 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Fortrea from In-line to Outperform and set a new price target of $25.00

    1/6/26 8:26:05 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Barclays with a new price target

    Barclays upgraded Fortrea from Underweight to Equal Weight and set a new price target of $15.00

    12/15/25 9:05:06 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call

    DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following ea

    1/29/26 8:08:01 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference

    DURHAM, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced an updated presentation time of 11:15 am PST on Tuesday, January 13, 2026, at the J.P. Morgan Annual Healthcare Conference (San Francisco). CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the conference. The live webcast and replay can be accessed through the "Events" section of Fortrea's  Investor Relations website. Investors interested in one-on-one meetings should contact their banking representatives. About Fortrea Fortrea (NASDAQ:FTRE) is a leading global provider of clinical development

    1/9/26 11:24:21 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea to Present at Upcoming J.P. Morgan Healthcare Conference

    DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the following conference in January: J.P. Morgan Annual Healthcare Conference (San Francisco)Date:Tuesday, January 13, 2025Time:5:15 pm PSTFormat:Presentation and Q&A   The live webcast and replay can be accessed through the "Events" section of Fortrea's Investor Relations website. Investors interested in one-on-one meetings should contact their banking representatives. About FortreaFortrea (NASDAQ:FTRE) is a leading global provider of clinic

    1/6/26 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Russell Erin L bought $100,018 worth of shares (9,854 units at $10.15) (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/4/25 4:39:23 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Director Neupert Peter M bought $407,150 worth of shares (62,500 units at $6.51), increasing direct ownership by 175% to 98,132 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    8/11/25 8:21:29 PM ET
    $FTRE
    Medical Specialities
    Health Care

    General Counsel Hanson James S. bought $50,600 worth of shares (2,000 units at $25.30), increasing direct ownership by 37% to 7,475 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    6/12/24 6:28:42 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    SEC Filings

    View All

    SEC Form 144 filed by Fortrea Holdings Inc.

    144 - Fortrea Holdings Inc. (0001965040) (Subject)

    1/20/26 3:30:32 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Fortrea Holdings Inc. (0001965040) (Filer)

    11/20/25 4:11:54 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Fortrea Holdings Inc.

    SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)

    11/14/25 11:22:58 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Morais Mark A. converted options into 2,255 shares and sold $16,365 worth of shares (1,179 units at $13.88), increasing direct ownership by 2% to 58,052 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    2/11/26 7:04:31 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Chief Financial Officer Mcconnell Jill G. sold $12,229 worth of shares (881 units at $13.88) and converted options into 1,685 shares, increasing direct ownership by 1% to 59,574 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    2/11/26 7:02:25 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form 4 filed by Director Sharbaugh William J

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    11/24/25 4:03:48 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fortrea Holdings Inc.

    SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)

    11/12/24 9:55:14 AM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    5/28/24 5:10:47 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    2/26/24 7:01:18 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Leadership Updates

    Live Leadership Updates

    View All

    Fortrea Appoints Agnieszka Gallagher as General Counsel

    DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M. Gallagher as general counsel. Gallagher is responsible for the Company's legal strategy and operations, serving as corporate secretary, chief compliance officer and as a member of Fortrea's leadership team. She succeeds J. Stillman Hanson, who is leaving the Company after a planned transition period. "Aggie brings broad and deep executive experience in the life sciences and beyond to Fortrea, with a track record of navigating complexity in global companies," said Anshul Thakral, CEO of Fortrea.

    11/17/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints William Sharbaugh to Board of Directors

    DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company's Board of Directors. Mr. Sharbaugh brings extensive healthcare experience in finance, operations, manufacturing, and quality to the position, having served in executive and board roles during his more than three decades in the pharmaceutical industry. "I'm delighted to welcome Bill to the Fortrea Board, bringing an impressive background in CRO and pharmaceutical operations," said Anshul Thakral, CEO of Fortrea. "He is a highly respected leader, who understands our stakeholders a

    9/22/25 4:30:50 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations

    DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue other career opportunities. Krumme will report to Chief Financial Officer, Jill McConnell, and lead Fortrea's global investor relations strategy, serving as a key liaison to the investment community. "Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter," said McConnell. "She brings not only deep capital markets expertise but also integrity, insi

    8/5/25 6:00:02 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Financials

    Live finance-specific insights

    View All

    Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call

    DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following ea

    1/29/26 8:08:01 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Reports Third Quarter 2025 Results

    For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 millionGAAP net loss of $(15.9) millionAdjusted EBITDA of $50.7 millionGAAP and adjusted net (loss) income per diluted share of $(0.17) and $0.12, respectivelyBook-to-bill ratio of 1.13x, resulting in 1.07x book-to-bill for the trailing 12 monthsCost saving initiatives remain on trackRaising 2025 revenue guidance to a range of $2,700 million to $2,750 million; narrowing 2025 adjusted EBITDA guidance to a range of $175 million to $195 million DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported

    11/5/25 6:30:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Date for Third Quarter 2025 Financial Results and Conference Call

    DURHAM, N.C., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast

    10/15/25 7:00:24 AM ET
    $FTRE
    Medical Specialities
    Health Care